Fig. 1

Comparison of the incidence of grade ≥ 2 AEs affecting QOL (i.e., nausea, peripheral neuropathy, pain) (A) and the average of EQ-5D-5 L utility value (B), before and after pharmaceutical intervention (B: Wilcoxon signed-rank test)